KOAN
Resonate Blends, Inc.0.0044
+0.0002+4.76%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
1.13MP/E (TTM)
-Basic EPS (TTM)
-0.02Dividend Yield
0%Recent Filings
10-Q
Q1 FY2025 results
Resonate Blends posted Q1 sales of $430,768, up sharply from $95,050 y/y, with gross profit climbing to $290,043 from $63,846 as COGS rose less dramatically. Operating loss narrowed to $(330,242) from $(416,828), yet net loss hit $(411,818) versus $(3,688,470) last year—smaller mainly due to no massive Emergent Health acquisition charge, though interest expense ate $81,791. Cash grew to $18,117 on $10,069 net inflow, fueled by $350,000 notes payable proceeds offsetting operating outflows; debt remains heavy at ~$5.4M current liabilities. Shares exploded 77% q/q to 195M on conversions. Operating cash used $236,055. Weak controls persist.
10-K
FY2024 results
Resonate Blends posted $1,349,905 in unaudited nine-month revenue through September 30, 2024, all from the March 14 EMGE acquisition, vaulting from $16,468 the prior year—yet Q4 details remain undisclosed in the 10-K. Gross profit hit $872,826 on $477,079 costs, but operating expenses exploded to $2,219,787, driving a $1,555,767 net loss amid $208,805 other expenses. Year-end cash sat at $68,236 against $4.6M current liabilities and a $3.5M working capital deficit, fueled by high-interest convertible notes. Auditors flag going concern doubts. Capital remains scarce.
8-K
CEO resigns; turnaround specialist steps in
Resonate Blends ousted President/CEO James Morrison effective March 5, 2025; he stays on the board with no disagreements cited. Board tapped director James W. Zimbler, 59, as replacement, tasking him to slash liabilities, negotiate with creditors, and scout mergers for solvency. Zimbler's M&A consulting background fits the turnaround push.
10-Q
Q3 FY2025 results
Resonate Blends posted Q3 sales of $598.6k, up from zero a year ago, driving gross profit to $419.5k yet an operating loss of $269.8k amid $689.2k expenses; nine-month revenue hit $1.35M (y/y +8,100%, derived) but netted a $1.56M loss, wider than 2023's $1.01M on interest and derivative hits exceeding operating shortfalls by over 20%. EMGE assets, acquired March 2024 and reformed to share-for-asset August 2024 for Evolutionary Biologics, Apollo Biowellness, Nanosthetic, and Nanogistics stock, fuel the ramp. Cash sits at $68k; debt tops $4.5M including convertibles and related-party notes, with $970k stuck in Pegasus advances. Financing dependence looms large.
10-Q
Q2 FY2024 results
Resonate Blends posted Q2 sales of $656K, up sharply from $6K y/y, driving gross profit to $390K while operations lost $709K amid $1.1M expenses from consulting and commissions. Six-month revenue hit $751K (derived +4.6% q/q), but net loss widened to $1.25M from $783K y/y, with the gap to operating loss tied to $107K interest and $140K derivative changes. Cash sits at $17K; liabilities swelled to $4.1M including $1.5M convertibles, offset by $914K financing inflows yet $436K operating burn. EMGE asset swap closed March 2024, reformed August for biologics firms. Controls remain weak.
IPO
Sector
Industry
BIOE
Bio Essence Corp.
0.05+0.00
BON
Bon Natural Life Limited
1.79+0.04
BSEM
BioStem Technologies, Inc.
3.84-0.11
CRLBF
Cresco Labs Inc.
1.75+0.45
GSTK
Growth Stalk Holdings Corp
3.00+0.00
HYEX
HEALTHY EXTRACTS INC.
1.99-0.22
ORGO
Organogenesis Holdings Inc.
5.17+0.34
PHBI
Pharmagreen Biotech Inc.
0.00+0.00
PLSH
Panacea Life Sciences Holdings,
0.09+0.00
RGC
Regencell Bioscience Holdings L
16.70-0.56